DrugPatentWatch Database Preview
ELIQUIS Drug Profile
Email this page to a colleague
» See Plans and PricingWhich patents cover Eliquis, and when can generic versions of Eliquis launch?
Eliquis is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and sixty-one patent family members in forty-two countries.
The generic ingredient in ELIQUIS is apixaban. There are thirty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the apixaban profile page.
US ANDA Litigation and Generic Entry Outlook for Eliquis
A generic version of ELIQUIS was approved as apixaban by MICRO LABS on December 23rd, 2019.
Summary for ELIQUIS
| International Patents: | 161 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 5 |
| Bulk Api Vendors: | 105 |
| Clinical Trials: | 58 |
| Patent Applications: | 1,073 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ELIQUIS |
| Drug Sales Revenues: | Drug sales revenues for ELIQUIS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ELIQUIS |
| DailyMed Link: | ELIQUIS at DailyMed |
Recent Clinical Trials for ELIQUIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of North Carolina, Chapel Hill | Phase 1 |
| ACCP Research Institute | Phase 1 |
| Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network | Phase 2 |
Pharmacology for ELIQUIS
| Drug Class | Factor Xa Inhibitor |
| Mechanism of Action | Factor Xa Inhibitors |
US Patents and Regulatory Information for ELIQUIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | |
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-002 | Dec 28, 2012 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ELIQUIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | Start Trial | Start Trial |
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-002 | Dec 28, 2012 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ELIQUIS
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | PA01006502 | Start Trial |
| World Intellectual Property Organization (WIPO) | 03026652 | Start Trial |
| Austria | 280171 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ELIQUIS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1427415 | C20110017 00045 | Estonia | Start Trial | PRODUCT NAME: ELIQUIS - APIKSABAAN; REG NO/DATE: C(2011)3595 18.05.2011 |
| 1427415 | C01427415/01 | Switzerland | Start Trial | FORMER OWNER: BRISTOL-MYERS SQUIBB COMPANY, US |
| 1427415 | PA2011012,C1427415 | Lithuania | Start Trial | PRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005, 0110518 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
